Production & Sales

AstraZeneca sells US, Canada rights of Seroquel drugs to Cheplapharm

AstraZeneca has signed a deal worth up to $41m to divest the US and Canada commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) to German pharma company Cheplapharm Arzneimittel.

STADA to acquire Biopharma’s prescription and consumer health business

STADA Group, a German generic drug manufacturer, has agreed to acquire the prescription and consumer health business of Ukrainian pharmaceutical producer Biopharma for an undisclosed price.

Novartis opens new cell and gene therapies facility in Switzerland

Swiss pharmaceutical company Novartis has opened a new manufacturing facility for cell and gene therapies at Stein in Switzerland.

Asahi Kasei to acquire Veloxis Pharmaceuticals for $1.3bn

Japan-based Asahi Kasei Group has signed an agreement to acquire Danish pharma company Veloxis Pharmaceuticals for DKK8.9bn ($1.3bn) in an all-cash deal.

Lupin to sell its stake in Kyowa to Unison for $526m

Lupin has signed a definitive agreement to sell the entire stake in its Japanese subsidiary Kyowa Pharmaceutical to Unison, a Japanese private equity fund, for JPY57.36bn ($526m).

Novartis’ Sandoz to buy Aspen’s Japanese business in $441m deal

Novartis division Sandoz has signed a binding agreement to acquire Aspen Global’s Japanese business in a deal valued at around €400m ($441m).

Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates

Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia.

Japan’s Takeda opens dengue vaccine manufacturing facility in Germany

Japan-based Takeda Pharmaceutical has opened a new dengue vaccine manufacturing facility in Singen, Germany.

Samsung Biologics and Ichnos Sciences announce agreement for manufacture of ISB 830

Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis.